Company Filing History:
2 out of 378 
2 out of 12,160 
Years Active: 2019-2022
Title: Maximillian Andreas Kullmann: Innovator in Medicinal Chemistry
Introduction
Maximillian Andreas Kullmann is a notable inventor based in Leichlingen, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of novel compounds for the treatment of various diseases. With a total of 2 patents to his name, Kullmann's work focuses on innovative solutions for cardiovascular and renal disorders.
Latest Patents
Kullmann's latest patents include the following:
1. **7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof** - This patent relates to novel 7-substituted 1-arylnaphthyridine-3-carboxamides, detailing processes for their preparation and their application in the treatment and prevention of diseases, particularly cardiovascular and renal disorders.
2. **7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof** - Similar to his first patent, this invention focuses on 7-substituted 1-pyridylnaphthyridine-3-carboxamides, outlining their preparation and use in the production of medicaments aimed at treating cardiovascular and renal disorders.
Career Highlights
Throughout his career, Kullmann has worked with prominent companies in the pharmaceutical industry, including Bayer Pharma Aktiengesellschaft and Bayer Aktiengesellschaft. His experience in these organizations has allowed him to develop and refine his innovative ideas in medicinal chemistry.
Collaborations
Kullmann has collaborated with several professionals in his field, including Henrik Teller and Melissa Boultadakis Arapinis. These collaborations have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Maximillian Andreas Kullmann is a distinguished inventor whose work in medicinal chemistry has the potential to significantly impact the treatment of cardiovascular and renal disorders. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.